Ganymede develops monoclonal antibodies for tumor and cancer therapy. The resulting therapeutics are highly effective against specific targets, which have been investigated and validated in more than ten years of scientific work. At the same time, the antibodies are characterized by advantageous side effect profiles with high potency.
MIG invests in Ganymed 2006
Exit to Astellas Pharma Inc. 2016